| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
ASN-002_Hydrochloride manufacturers
- Gusacitinib HCl
-
- $1980.00
-
2026-07-27
- CAS:2228989-14-6
- Purity:
- Supply Ability: 10g
|
| | ASN-002_Hydrochloride Basic information |
| Product Name: | ASN-002_Hydrochloride | | Synonyms: | ASN-002_Hydrochloride;ASN-002 HCl;1-[5,6-Dihydro-4-[[4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5-oxopyrimido[4,5-d]pyridazin-2-yl]-4-piperidineacetonitrile,hydrochloride (1:1);Gusacitinib hydrochloride;Gusacitinib HCl | | CAS: | 2228989-14-6 | | MF: | C24H29ClN8O2 | | MW: | 497 | | EINECS: | | | Product Categories: | | | Mol File: | 2228989-14-6.mol |  |
| | ASN-002_Hydrochloride Chemical Properties |
| | ASN-002_Hydrochloride Usage And Synthesis |
| Uses | Gusacitinib (ASN-002) hydrochloride is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib hydrochloride rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib hydrochloride can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma[1][2]. | | in vivo | Gusacitinib hydrochloride exhibits significant efficacy in inhibiting tumor growth (>95%), in a multiple myeloma (H929) xenograft model[3].
Gusacitinib hydrochloride significantly delays the onset of hind limb paralysis in the human erythroleukemia (HEL) mouse model[3].
Gusacitinib hydrochloride shows a favorable safety profile in rat and dog toxicology studies[3]. | | References | [1] Xie Z, et al. Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. J Med Chem. 2021 Feb 11;64(3):1283-1345. DOI:10.1021/acs.jmedchem.0c01511
[2] Garcia-Melendo C, et al. Janus Kinase Inhibitors in Dermatology: Part 1 - General Considerations and Applications in Vitiligo and Alopecia Areata. Actas Dermo-Sifiliográficas, 2021, 112(6): 503-515.
[3] Sanjeeva Reddy, et al. Abstract 792: ASN002: A novel dual SYK/JAK inhibitor with strong antitumor activity. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. |
| | ASN-002_Hydrochloride Preparation Products And Raw materials |
|